AR109714A1 - Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso - Google Patents
Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su usoInfo
- Publication number
- AR109714A1 AR109714A1 ARP170102642A ARP170102642A AR109714A1 AR 109714 A1 AR109714 A1 AR 109714A1 AR P170102642 A ARP170102642 A AR P170102642A AR P170102642 A ARP170102642 A AR P170102642A AR 109714 A1 AR109714 A1 AR 109714A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- pharmaceutically acceptable
- mglur2
- compound
- Prior art date
Links
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title abstract 3
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229940126662 negative allosteric modulator Drugs 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003016 chromanyl group Chemical class O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical class C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036963 noncompetitive effect Effects 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical class C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud proporciona compuestos de cromano, isocromano y dihidroisobenzofurano sustituidos o una sal farmacéuticamente aceptable de los mismos. Los compuestos son útiles como antagonistas de mGluR2 no competitivos, o moduladores alostéricos negativos de mGluR2 (NAM), y pueden ser útiles en procedimientos de tratamiento de un paciente para enfermedades o trastornos en los que está implicado el receptor mGluR2-NAM, tales como la enfermedad de Alzheimer, deterioro cognitivo, esquizofrenia y otros trastornos del estado de ánimo, trastornos del dolor y trastornos del sueño, mediante la administración al paciente de una cantidad terapéuticamente eficaz de un compuesto de la presente, o una sal farmacéuticamente aceptable del mismo. También se refiere a composiciones farmacéuticas que comprenden un compuesto, o una sal farmacéuticamente aceptable del mismo, (opcionalmente en combinación con uno o más ingredientes activos adicionales), y un vehículo farmacéuticamente aceptable, y al uso de los compuestos y composiciones farmacéuticas en el tratamiento de tales enfermedades. Reivindicación 1: Un compuesto de fórmula (1), o un estereoisómero del mismo o una sal farmacéuticamente aceptable de dicho compuesto o dicho estereoisómero, en la que el anillo A es un resto seleccionado de: los compuestos del grupo de fórmulas (2), en los que: R² se selecciona de H, ciclopropilo, -alquilo C₁₋₄, -alquil C₁₋₄-OH, -alquil C₁₋₄-OCH₃, -halógenoalquilo C₁₋₄, -alquil C₁₋₄-O-halógenoalquilo C₁₋₄, -CH(CH₃)₂, -CH₂-O-halógenoalquilo C₁₋₄, -CH(CH₃)-O-halógenoalquilo C₁₋₄, -CH₂-NH-halógenoalquilo C₁₋₄ y -CH₂-N(CH₃)-halógenoalquilo C₁₋₄; R²A se selecciona de H y metilo; R³ se selecciona de H y metilo; R³A se selecciona de H y metilo; el anillo B es un resto seleccionado del grupo consistente en fenilo, heteroarilo, cicloalquilo -C₅₋₆ y cicloalquenilo -C₅₋₆; n es 0, 1, 2 ó 3, con la condición de que el valor de n no supere el número máximo de átomos de hidrógeno sustituibles en el anillo B; y cada R¹ (cuando está presente) se selecciona independientemente del grupo consistente en halógeno, -CN, -OH, alquilo -C₁₋₆, -O-alquilo C₁₋₆, -halógenoalquilo C₁₋₆, -O-halógenoalquilo C₁₋₆, ciclopropilo, ciclobutilo, -NH₂, -NH-alquilo C₁₋₆, -N-(alquilo C₁₋₆)₂, -C(O)O-alquilo C₁₋₆ y fenilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400150P | 2016-09-27 | 2016-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109714A1 true AR109714A1 (es) | 2019-01-16 |
Family
ID=60043302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102642A AR109714A1 (es) | 2016-09-27 | 2017-09-25 | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10335399B2 (es) |
| EP (1) | EP3519416B1 (es) |
| JP (3) | JP6681517B2 (es) |
| KR (1) | KR102296043B1 (es) |
| CN (1) | CN109983022B (es) |
| AR (1) | AR109714A1 (es) |
| AU (2) | AU2017334870C1 (es) |
| CA (1) | CA3037537C (es) |
| CL (1) | CL2019000778A1 (es) |
| CO (1) | CO2019002673A2 (es) |
| CR (1) | CR20190147A (es) |
| CY (1) | CY1124346T1 (es) |
| DK (1) | DK3519416T3 (es) |
| DO (1) | DOP2019000076A (es) |
| EA (1) | EA038627B1 (es) |
| EC (1) | ECSP19020742A (es) |
| ES (1) | ES2868973T3 (es) |
| GE (2) | GEP20217279B (es) |
| HR (1) | HRP20210793T1 (es) |
| HU (1) | HUE054898T2 (es) |
| IL (1) | IL265366B (es) |
| JO (1) | JOP20190058B1 (es) |
| LT (1) | LT3519416T (es) |
| MA (1) | MA46342B1 (es) |
| MD (1) | MD3519416T2 (es) |
| MX (1) | MX2019003492A (es) |
| MY (1) | MY196807A (es) |
| NI (1) | NI201900025A (es) |
| PE (1) | PE20190609A1 (es) |
| PH (1) | PH12019500597A1 (es) |
| PL (1) | PL3519416T3 (es) |
| PT (1) | PT3519416T (es) |
| RS (1) | RS61890B1 (es) |
| SI (1) | SI3519416T1 (es) |
| TN (2) | TN2020000161A1 (es) |
| TW (1) | TWI764934B (es) |
| UA (1) | UA123687C2 (es) |
| WO (1) | WO2018063955A1 (es) |
| ZA (1) | ZA201901701B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3037537C (en) * | 2016-09-27 | 2021-06-15 | Merck Sharp & Dohme Corp. | Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use |
| US10836755B2 (en) | 2018-01-19 | 2020-11-17 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| PE20212179A1 (es) * | 2019-03-01 | 2021-11-09 | Kbp Biosciences Co Ltd | Procedimiento para preparar un compuesto triciclico fusionado, e intermedio del mismo |
| AR125026A1 (es) | 2021-03-04 | 2023-05-31 | Cytokinetics Inc | Inhibidores del sarcómero cardíaco |
| WO2023278729A1 (en) * | 2021-06-30 | 2023-01-05 | The General Hospital Corporation | Chromane imaging ligands |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| CA2624294A1 (en) | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| BRPI0917394A2 (pt) | 2008-08-18 | 2019-09-24 | Univ Yale | moduladores de mif |
| CA2760741C (en) * | 2009-05-12 | 2018-05-01 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| RU2610262C2 (ru) | 2011-11-03 | 2017-02-08 | Мерк Шарп И Доум Корп. | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGLuR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| US10538491B2 (en) | 2015-03-16 | 2020-01-21 | Vanderbilt University | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators |
| JP6471614B2 (ja) | 2015-05-29 | 2019-02-20 | 株式会社リコー | 通信端末、通信システム、通信制御方法、及びプログラム |
| JP2018154554A (ja) | 2015-07-29 | 2018-10-04 | 大日本住友製薬株式会社 | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 |
| CA3037537C (en) * | 2016-09-27 | 2021-06-15 | Merck Sharp & Dohme Corp. | Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use |
-
2017
- 2017-09-25 CA CA3037537A patent/CA3037537C/en active Active
- 2017-09-25 AU AU2017334870A patent/AU2017334870C1/en active Active
- 2017-09-25 EA EA201990818A patent/EA038627B1/ru unknown
- 2017-09-25 WO PCT/US2017/053155 patent/WO2018063955A1/en unknown
- 2017-09-25 MA MA46342A patent/MA46342B1/fr unknown
- 2017-09-25 LT LTEP17781253.4T patent/LT3519416T/lt unknown
- 2017-09-25 MD MDE20190867T patent/MD3519416T2/ro unknown
- 2017-09-25 CR CR20190147A patent/CR20190147A/es unknown
- 2017-09-25 MY MYPI2019001659A patent/MY196807A/en unknown
- 2017-09-25 KR KR1020197011789A patent/KR102296043B1/ko active IP Right Grant
- 2017-09-25 ES ES17781253T patent/ES2868973T3/es active Active
- 2017-09-25 MX MX2019003492A patent/MX2019003492A/es unknown
- 2017-09-25 UA UAA201904545A patent/UA123687C2/uk unknown
- 2017-09-25 US US15/713,769 patent/US10335399B2/en active Active
- 2017-09-25 JO JOP/2019/0058A patent/JOP20190058B1/ar active
- 2017-09-25 HU HUE17781253A patent/HUE054898T2/hu unknown
- 2017-09-25 CN CN201780071759.0A patent/CN109983022B/zh active Active
- 2017-09-25 PT PT177812534T patent/PT3519416T/pt unknown
- 2017-09-25 PL PL17781253T patent/PL3519416T3/pl unknown
- 2017-09-25 RS RS20210649A patent/RS61890B1/sr unknown
- 2017-09-25 SI SI201730727T patent/SI3519416T1/sl unknown
- 2017-09-25 PE PE2019000706A patent/PE20190609A1/es unknown
- 2017-09-25 AR ARP170102642A patent/AR109714A1/es active IP Right Grant
- 2017-09-25 TN TNP/2020/000161A patent/TN2020000161A1/en unknown
- 2017-09-25 JP JP2019516203A patent/JP6681517B2/ja active Active
- 2017-09-25 TN TNP/2020/000160A patent/TN2020000160A1/en unknown
- 2017-09-25 EP EP17781253.4A patent/EP3519416B1/en active Active
- 2017-09-25 GE GEAP201715310A patent/GEP20217279B/en unknown
- 2017-09-25 DK DK17781253.4T patent/DK3519416T3/da active
- 2017-09-25 TW TW106132824A patent/TWI764934B/zh active
- 2017-09-25 GE GEAP201715056A patent/GEP20217266B/en unknown
-
2019
- 2019-03-13 IL IL265366A patent/IL265366B/en unknown
- 2019-03-19 PH PH12019500597A patent/PH12019500597A1/en unknown
- 2019-03-19 ZA ZA2019/01701A patent/ZA201901701B/en unknown
- 2019-03-20 NI NI201900025A patent/NI201900025A/es unknown
- 2019-03-22 CO CONC2019/0002673A patent/CO2019002673A2/es unknown
- 2019-03-25 CL CL2019000778A patent/CL2019000778A1/es unknown
- 2019-03-26 DO DO2019000076A patent/DOP2019000076A/es unknown
- 2019-03-28 EC ECSENADI201920742A patent/ECSP19020742A/es unknown
- 2019-04-23 US US16/392,131 patent/US10806724B2/en active Active
- 2019-09-30 JP JP2019178232A patent/JP6945605B2/ja active Active
-
2020
- 2020-03-23 JP JP2020051049A patent/JP6992109B2/ja active Active
- 2020-09-25 US US17/032,626 patent/US20210015800A1/en not_active Abandoned
- 2020-11-16 AU AU2020270468A patent/AU2020270468B2/en active Active
-
2021
- 2021-05-17 HR HRP20210793TT patent/HRP20210793T1/hr unknown
- 2021-05-31 CY CY20211100468T patent/CY1124346T1/el unknown
-
2022
- 2022-03-15 US US17/695,262 patent/US20220218676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109714A1 (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR116424A1 (es) | Moduladores de la somatostatina y usos de los mismos | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| AR099640A1 (es) | Derivados de pirrolopiridina o pirazolopiridina | |
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| AR084731A1 (es) | Derivados de imidazoquinolina sustituidos | |
| AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| PH12017502254A1 (en) | Pyrazole derivative or pharmaceutically acceptable salt thereof | |
| MX362192B (es) | Derivado de glicinamida alfa-sustituida. | |
| AR108535A1 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
| JP2015522556A5 (es) | ||
| RU2018130994A (ru) | Новое соединение бисфосфоновой кислоты | |
| AR113910A1 (es) | Derivados de o-fenoxi y o-benciloxipropilamino con actividad contra el dolor | |
| HRP20220458T1 (hr) | SPOJEVI 1,2,3′,5′-TETRAHIDRO-2′H-SPIRO[INDOL-3,1′-PIROLO[3,4-c]PIROL]-2,3′-DIONA KAO TERAPIJSKA SREDSTVA KOJA AKTIVIRAJU TP53 | |
| AR060473A1 (es) | Acidos 4-oxo-1, 4-dihidroquinolina como moduladores alostericos positivos del receptor m1, una composicion farmaceutica que los comprende y el uso de estos en la elaboracion de un medicamento para el tratamiento de la enfermedad de alzheimer, trastornos del dolor y del sueno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |